Clearside Biomedical (NASDAQ:CLSD) Given "Buy" Rating at HC Wainwright

Clearside Biomedical (NASDAQ:CLSD - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $6.00 target price on the stock.

Several other equities analysts have also weighed in on CLSD. StockNews.com raised shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Thursday, December 12th. Chardan Capital reaffirmed a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Thursday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $5.33.

Clearside Biomedical Price Performance

CLSD traded down $0.05 during trading on Thursday, reaching $0.88. 236,772 shares of the company's stock were exchanged, compared to its average volume of 381,254. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $2.12. The stock has a market capitalization of $66.73 million, a P/E ratio of -1.96 and a beta of 2.10. The company's fifty day simple moving average is $0.96 and its 200-day simple moving average is $1.05.

Remove Ads

Institutional Investors Weigh In On Clearside Biomedical

Several large investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company's stock valued at $726,000 after acquiring an additional 32,672 shares during the period. Northern Trust Corp boosted its holdings in shares of Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company's stock valued at $157,000 after acquiring an additional 32,048 shares during the period. Johnson & Johnson acquired a new stake in shares of Clearside Biomedical in the third quarter valued at approximately $105,000. Finally, Investor s Fiduciary Advisor Network LLC acquired a new stake in shares of Clearside Biomedical in the fourth quarter valued at approximately $32,000. 18.75% of the stock is owned by institutional investors and hedge funds.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.